Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(1.82) per share which missed the analyst consensus estimate of $(1.62) by 12.35 percent. This is a 49.72 percent increase over losses of $(3.62) per share from the same period last year. The company reported quarterly sales of $10.860 million which beat the analyst consensus estimate of $10.636 million by 2.10 percent. This is a 3.82 percent increase over sales of $10.460 million the same period last year.